Committee for Advanced Therapies (CAT)

The Committee for Advanced Therapies (CAT) is a multidisciplinary committee, gathering together some of the best available experts in Europe to assess the quality, safety and efficacy of advanced-therapy medicinal products (ATMPs) and follow scientific developments in the field.

It was established in accordance with Regulation (EC) No 1394/2007 on ATMPs.

• See the full overview of the CAT's role

Composition

The CAT is composed of:

• five members or co-opted members of the Committee for Medicinal Products for Human Use (CHMP), with their alternates. These members are appointed by the CHMP itself;
• one member and one alternate appointed by each European Union (EU) Member State that is not represented by the members and alternates appointed by the CHMP;
• two members and two alternates appointed by the European Commission to represent clinicians;
• two members and two alternates appointed by the European Commission to represent patient associations.

The members of the CAT are appointed for a renewable period of three years. The chair and vice-chair are elected from its members for a term of three years, which may be renewed once.

Meeting calendar

• See full meeting plan for this year